Tags: Drug.
Guselkumab is a monoclonal antibody designed for the treatment of psoriasis.Tildrakizumab was designed to block interleukin-23 a cytokine that plays an important role in managing the immune system and autoimmune disease. This drug was developed by Janssen Global Services LLC.As of March 2014 the drug was in phase II clinical trials for plaque psoriasis.